Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Ustekinumab, secukinumab trump other systemic drugs for psoriasis treatment

05 Jul 2020

A recent study has assessed the long-term safety of nine systemic medications for psoriasis, revealing the lowest incidence of adverse events with ustekinumab and secukinumab.

The authors characterized the findings on the systemic drugs acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab, methotrexate, secukinumab, and ustekinumab used for the treatment of moderate to severe psoriasis in patients included in the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM).

A prospective cohort was used to determine the incidence rate ratio (IRR) and adjusted IRR, including propensity scores, of identified adverse events for each drug, with methotrexate as the reference.

A total of 2,845 patients were included, which involved 8,954 treatment cycles over 9,642 patient-years. The lowest rate of adverse events for several of the system organ classes was observed with ustekinumab and secukinumab, with a statistically significant decreased rate ratio (IRR of <1).

On the other hand, the highest rate of adverse events was found with cyclosporine and infliximab, with an increased rate ratio (IRR of ≥5).

“Our data provide comparative safety information in the real-life setting that could help clinicians selecting between available products,” the authors said.

A network meta-analysis also showed that ustekinumab and secukinumab were the most effective medications for achieving Psoriasis Area and Severity Index score 90 in patients with moderate to severe psoriasis, along with ixekizumab, brodalumab, guselkumab, and certolizumab, compared with placebo. [Cochrane Database Syst Rev 2017;12:CD011535]

The current study was limited by its observational design and depletion of susceptibles, according to the authors. In addition, drug allocation was not randomized, and prescribed doses were not registered.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).